North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-04-02 Anti-androgens
| Dutasteride |
|
Formulary
|
|
 MHRA Drug Safety Update (May 2026): Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction |
|
| Cyproterone Acetate 50mg and 100mg tablets |
|
Formulary
|
|
|
MHRA Drug Safety Update (June 2020): Cyproterone acetate: new advice to minimise risk of meningioma |
|
Links
- County Durham & Tees Valley Primary Care Guidance for the Management of Hypogonadism
- MHRA Drug Safety Update (June 2020): Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA Drug Safety Update (May 2026): Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction
- MHRA Drug Safety Update (May 2026): Finasteride and Dutasteride – updated safety warnings for psychiatric side effects and sexual dysfunction
- MHRA Drug Safety Update (Jan 2023): Topical testosterone (Testogel): risk of harm to children following accidental exposure
NENC ICB - Management of the Menopause - NENC ICB - Management of the Menopause
- NENC ICB - Management of the Menopause
- NICE CG97 Lower urinary tract symptoms: quick reference guide
- NICE NG23: Menopause: diagnosis and management
- NTAG Endocrine System Recommendations